Sheila Fisher
Overview
Explore the profile of Sheila Fisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
7589
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beyer J, Lind S, Fisher S, Trujillo T, Wempe M, Kiser T
J Thromb Thrombolysis
. 2019 Sep;
49(2):259-267.
PMID: 31559512
The parenterally administered direct thrombin inhibitors (DTIs) argatroban and bivalirudin are effective anticoagulants for acute heparin-induced thrombocytopenia (HIT) treatment. The activated partial thromboplastin time (aPTT) has classically been used as...
2.
Beyer J, Trujillo T, Fisher S, Ko A, Lind S, Kiser T
Clin Appl Thromb Hemost
. 2016 Feb;
22(5):423-8.
PMID: 26842561
The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has significantly impacted the treatment and prevention of thromboembolic disease. Clinical scenarios exist in which a quantitative assessment for degree...
3.
Brat D, Verhaak R, Aldape K, Yung W, Salama S, Cooper L, et al.
N Engl J Med
. 2015 Jun;
372(26):2481-98.
PMID: 26061751
Background: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted...
4.
Ness A, Waylen A, Hurley K, Jeffreys M, Penfold C, Pring M, et al.
BMC Cancer
. 2014 Dec;
14:973.
PMID: 25519023
Background: Head and neck cancer is an important cause of ill health. Survival appears to be improving but the reasons for this are unclear. They could include evolving aetiology, modifications...
5.
Singer S, Araujo C, Arraras J, Baumann I, Boehm A, Herlofson B, et al.
Head Neck
. 2014 May;
37(9):1358-67.
PMID: 24832623
Background: The objective of this study was to pilot test an updated version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck...
6.
Lind S, Boyle M, Fisher S, Ishimoto J, Trujillo T, Kiser T
Am J Clin Pathol
. 2014 Apr;
141(5):665-74.
PMID: 24713737
Objectives: The activated partial thromboplastin time (aPTT) test has been used for years to monitor parenteral direct thrombin inhibitors (DTIs) and unfractionated heparin. Because the aPTT correlates poorly with unfractionated...
7.
Wagle N, Van Allen E, Treacy D, Frederick D, Cooper Z, Taylor-Weiner A, et al.
Cancer Discov
. 2013 Nov;
4(1):61-8.
PMID: 24265154
Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP-ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with...
8.
Costello M, Pugh T, Fennell T, Stewart C, Lichtenstein L, Meldrim J, et al.
Nucleic Acids Res
. 2013 Jan;
41(6):e67.
PMID: 23303777
As researchers begin probing deep coverage sequencing data for increasingly rare mutations and subclonal events, the fidelity of next generation sequencing (NGS) laboratory methods will become increasingly critical. Although error...
9.
Garber M, Yosef N, Goren A, Raychowdhury R, Thielke A, Guttman M, et al.
Mol Cell
. 2012 Sep;
47(5):810-22.
PMID: 22940246
Understanding the principles governing mammalian gene regulation has been hampered by the difficulty in measuring in vivo binding dynamics of large numbers of transcription factors (TF) to DNA. Here, we...
10.
Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A, et al.
Nature
. 2011 Feb;
470(7333):214-20.
PMID: 21307934
Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we...